Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Annals of Hematology
|
May 1, 1993
Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics
P P Brons, C Haanen, J B Boezeman, et al.
Leukemia
|
January 1, 1992
Therapy of adult ALL: overview of 2 successive EORTC studies: (ALL-2 & ALL-3). The EORTC Leukemia Cooperative Study Group
P Stryckmans, T De Witte, J P Marie, et al.
Blood
|
March 15, 1990
Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation
A Schattenberg, T De Witte, F Preijers, et al.
Bone Marrow Transplantation
|
August 1, 1997
Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial
R Zittoun, S Suciu, M Watson, et al.
Biochimica Et Biophysica Acta
|
September 13, 1993
Regulation of the expression of mitochondrial proteins: relationship between mtDNA copy number and cytochrome-c oxidase activity in human cells and tissues
C Van den Bogert, H De Vries, M Holtrop, et al.
Annals of Hematology
|
March 1, 1996
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group
T De Witte, S Suciu, D Selleslag, et al.
Annals of Hematology
|
April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
R Willemze, S Suciu, P Muus, et al.
Internal Medicine Journal
|
June 16, 2016
Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry
G Socié, H Schrezenmeier, P Muus, et al.
Leukemia
|
March 1, 1997
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)
R Willemze, S Suciu, E Archimbaud, et al.
Blood
|
November 5, 1997
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group
B Löwenberg, S Suciu, E Archimbaud, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Annals of Hematology
|
May 1, 1993
Proliferation patterns in acute myeloid leukemia: leukemic clonogenic growth and in vivo cell cycle kinetics
P P Brons, C Haanen, J B Boezeman, et al.
Leukemia
|
January 1, 1992
Therapy of adult ALL: overview of 2 successive EORTC studies: (ALL-2 & ALL-3). The EORTC Leukemia Cooperative Study Group
P Stryckmans, T De Witte, J P Marie, et al.
Blood
|
March 15, 1990
Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation
A Schattenberg, T De Witte, F Preijers, et al.
Bone Marrow Transplantation
|
August 1, 1997
Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial
R Zittoun, S Suciu, M Watson, et al.
Biochimica Et Biophysica Acta
|
September 13, 1993
Regulation of the expression of mitochondrial proteins: relationship between mtDNA copy number and cytochrome-c oxidase activity in human cells and tissues
C Van den Bogert, H De Vries, M Holtrop, et al.
Annals of Hematology
|
March 1, 1996
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group
T De Witte, S Suciu, D Selleslag, et al.
Annals of Hematology
|
April 1, 2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial)
R Willemze, S Suciu, P Muus, et al.
Internal Medicine Journal
|
June 16, 2016
Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry
G Socié, H Schrezenmeier, P Muus, et al.
Leukemia
|
March 1, 1997
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)
R Willemze, S Suciu, E Archimbaud, et al.
Blood
|
November 5, 1997
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group
B Löwenberg, S Suciu, E Archimbaud, et al.
Page
of 7